| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-47846-0.1mg | |||
| IHC-Prediluted | NBP2-48063 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44426 | |||
| Azide and BSA Free | NBP2-34425-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50052SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2618SS | |||
| Azide and BSA Free | NBP2-80817 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19083SS | |||
![Immunohistochemistry-Paraffin: Chromogranin A Antibody (CGA/413 + CHGA/777 + CHGA/798) [NBP2-44764] - Pheochromocytoma stained with Chromogranin A Monoclonal Antibody (CGA/413+ CHGA/777+ CHGA/798)](http://images.novusbio.com/fullsize/Chromogranin-A-Antibody-CGA-413-+-CHGA-777-+-CHGA-798-Immunohistochemistry-Paraffin-NBP2-44764-img0004.jpg "Immunohistochemistry-Paraffin: Chromogranin A Antibody (CGA/413 + CHGA/777 + CHGA/798) [NBP2-44764] - Pheochromocytoma stained with Chromogranin A Monoclonal Antibody (CGA/413+ CHGA/777+ CHGA/798)")
![Immunohistochemistry-Paraffin: Chromogranin A Antibody (CGA/413 + CHGA/777 + CHGA/798) [NBP2-44764] - Adrenal Gland stained with Chromogranin A Monoclonal Antibody (CGA/413+ CHGA/777+ CHGA/798)](http://images.novusbio.com/fullsize/Chromogranin-A-Antibody-CGA-413-+-CHGA-777-+-CHGA-798-Immunohistochemistry-Paraffin-NBP2-44764-img0001.jpg)
![Immunohistochemistry-Paraffin: Chromogranin A Antibody (CGA/413 + CHGA/777 + CHGA/798) [NBP2-44764] - Pancreas stained with Chromogranin A Monoclonal Antibody (CGA/413+ CHGA/777+ CHGA/798)](http://images.novusbio.com/fullsize/Chromogranin-A-Antibody-CGA-413-+-CHGA-777-+-CHGA-798-Immunohistochemistry-Paraffin-NBP2-44764-img0002.jpg)
![Immunohistochemistry-Paraffin: Chromogranin A Antibody (CGA/413 + CHGA/777 + CHGA/798) [NBP2-44764] - Parathyroid stained with Chromogranin A Monoclonal Antibody (CGA/413+ CHGA/777+ CHGA/798)](http://images.novusbio.com/fullsize/Chromogranin-A-Antibody-CGA-413-+-CHGA-777-+-CHGA-798-Immunohistochemistry-Paraffin-NBP2-44764-img0003.jpg)
![Western Blot: Cytokeratin 17 Antibody (SPM560) [NBP2-34378] - Western blot of HeLa lysate using CK17 Ab (SPM560).](http://images.novusbio.com/fullsize/Cytokeratin-17-Antibody-SPM560-Western-Blot-NBP2-34378-img0003.jpg "Western Blot: Cytokeratin 17 Antibody (SPM560) [NBP2-34378] - Western blot of HeLa lysate using CK17 Ab (SPM560).")
![Immunohistochemistry-Paraffin: Cytokeratin 17 Antibody (SPM560) [NBP2-34378] - Formalin-paraffin skin stained with CK17 MAb (SPM560).](http://images.novusbio.com/fullsize/Cytokeratin-17-Antibody-SPM560-Immunohistochemistry-Paraffin-NBP2-34378-img0002.jpg)
![Flow Cytometry: Cytokeratin 17 Antibody (SPM560) [NBP2-34378] - Flow Cytometric Analysis of PFA-fixed HeLa cells labeling CK17 with Cytokeratin 17 Antibody (SPM560) followed by Goat anti-Mouse IgG-CF488 (Blue) Isotype Control (Red)](http://images.novusbio.com/fullsize/Cytokeratin-17-Antibody-SPM560-Flow-Cytometry-NBP2-34378-img0004.jpg)
![Immunohistochemistry-Paraffin: Cytokeratin 17 Antibody (SPM560) [NBP2-34378] - Formalin-paraffin skin stained with CK17 Ab (SPM560).](http://images.novusbio.com/fullsize/Cytokeratin-17-Antibody-SPM560-Immunohistochemistry-Paraffin-NBP2-34378-img0001.jpg)
![Western Blot: GAP-43 Antibody (5E8) [NBP2-50052] - Analysis of different tissue and cell lysates using mouse mAb to GAP43, NBP2-50052, dilution 1:2,000, in green: [1] protein standard (red), [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord, [6] C6 cells, [7] SH-SY5Y cells. Single band at 43 kDa mark correspond to GAP43 protein. The protein is expressed in rodent and human neurons and neuronal derived cells but not in C6 cells which are of glial origin.](http://images.novusbio.com/fullsize/GAP-43-Antibody-5E8-Western-Blot-NBP2-50052-img0005.jpg "Western Blot: GAP-43 Antibody (5E8) [NBP2-50052] - Analysis of different tissue and cell lysates using mouse mAb to GAP43, NBP2-50052, dilution 1:2,000, in green: [1] protein standard (red), [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord, [6] C6 cells, [7] SH-SY5Y cells. Single band at 43 kDa mark correspond to GAP43 protein. The protein is expressed in rodent and human neurons and neuronal derived cells but not in C6 cells which are of glial origin.")
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody (5E8) [NBP2-50052] - Analysis of cortical neuron-glial cell culture from E20 rat stained with mouse mAb to GAP43, NBP2-50052, dilution 1:1,000, in red, and costained with chicken pAb to GFAP, dilution 1:2,000, in green. The blue is DAPI staining of nuclear DNA. GAP43 antibody labels protein expressed in the axonal membrane of the neuronal cells, and GFAP antibody stains astroglia.](http://images.novusbio.com/fullsize/GAP-43-Antibody-5E8-Immunocytochemistry-Immunofluorescence-NBP2-50052-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody (5E8) [NBP2-50052] - Mixed rat neuronal cultures stained with NBP2-50052 (green). The GAP43 antibody stains the plasma membrane of neurons and is particularly concentrated in dendrites.](http://images.novusbio.com/fullsize/GAP-43-Antibody-5E8-Immunocytochemistry-Immunofluorescence-NBP2-50052-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Integrin alpha V/CD51 Antibody (P2W7) [NB100-2618] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Integrin alpha V/CD51 Antibody [P2W7] (NB100-2618) at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Integrin-alpha-V-CD51-Antibody-P2W7-Immunocytochemistry-Immunofluorescence-NB100-2618-img0001.jpg "Immunocytochemistry/Immunofluorescence: Integrin alpha V/CD51 Antibody (P2W7) [NB100-2618] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Integrin alpha V/CD51 Antibody [P2W7] (NB100-2618) at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Western Blot: TCF7L2 Antibody [NBP1-19083] - Western blot analysis of TCF7L2 (F) protein in D3H2LN TNBC cells after treatment with SCR or SID decoy peptide (2.5uM, 24 hours). SID decoy treatment inhibited full-length (~64 kDa) and, to a greater extent, short isoform variant (~53 kDa) TCF7L2 proteins in comparison to untreated or SCR treated controls. The band intensities for TCF7L2 in each lane were normalized to the GAPDH loading control and indicated in red. The result is representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11381) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TCF7L2-Antibody-Western-Blot-NBP1-19083-img0005.jpg "<b>Biological Strategies Validation. </b>Western Blot: TCF7L2 Antibody [NBP1-19083] - Western blot analysis of TCF7L2 (F) protein in D3H2LN TNBC cells after treatment with SCR or SID decoy peptide (2.5uM, 24 hours). SID decoy treatment inhibited full-length (~64 kDa) and, to a greater extent, short isoform variant (~53 kDa) TCF7L2 proteins in comparison to untreated or SCR treated controls. The band intensities for TCF7L2 in each lane were normalized to the GAPDH loading control and indicated in red. The result is representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11381) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: TCF7L2 Antibody [NBP1-19083] - TCF7L2 antibody was tested in Hela cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/TCF7L2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19083-img0004.jpg)
![Western Blot: TCF7L2 Antibody [NBP1-19083] - Jurkat cell line.](http://images.novusbio.com/fullsize/TCF7L2-Antibody-Western-Blot-NBP1-19083-img0003.jpg)
![Immunohistochemistry-Paraffin: Rad51 Antibody [NBP2-20058] - Human ovarian carcinoma. Rad51 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/Rad51-Antibody-Immunohistochemistry-Paraffin-NBP2-20058-img0005.jpg "Immunohistochemistry-Paraffin: Rad51 Antibody [NBP2-20058] - Human ovarian carcinoma. Rad51 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min")
![Western Blot: Rad51 Antibody [NBP2-20058] - Sample (30 ug of whole cell lysate) A: JurKat 10% SDS PAGE gel, diluted at 1:1000.](http://images.novusbio.com/fullsize/Rad51-Antibody-Western-Blot-NBP2-20058-img0001.jpg)
![Immunohistochemistry-Paraffin: Rad51 Antibody [NBP2-20058] - Human breast carcinoma. Rad51 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/Rad51-Antibody-Immunohistochemistry-Paraffin-NBP2-20058-img0004.jpg)
![Rad51 antibody immunoprecipitates Rad51 protein in IP experiments.IP samples: Jurkat whole cell extractA. 40 ug Jurkat whole cell extractB. Control with 4 ug of preimmune Rabbit IgGC. Immunoprecipitation of Rad51 protein by 4 ug Rad51 antibody (NBP2-20058)5 % SDS-PAGEThe immunoprecipitated Rad51 protein was detected by Rad51 antibody (NBP2-20058) diluted at 1:500.[EasyBlot anti-rabbit IgG was used as a secondary reagent]](http://images.novusbio.com/fullsize/nbp2-20058_rabbit-polyclonal-rad51-antibody-immunoprecipitation-261120251843455.jpg)
![Western Blot: SR-BI Antibody (SR37-06) [NBP3-11865] - Western blot analysis of SR-BI on different lysates using NBP3-11865 at 1/1,000 dilution. Positive control: Lane 1: Human liver. Lane 2: Mouse liver](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Western-Blot-NBP3-11865-img0001.jpg "Western Blot: SR-BI Antibody (SR37-06) [NBP3-11865] - Western blot analysis of SR-BI on different lysates using NBP3-11865 at 1/1,000 dilution. Positive control: Lane 1: Human liver. Lane 2: Mouse liver")
![Immunocytochemistry/Immunofluorescence: SR-BI Antibody (SR37-06) [NBP3-11865] - Immunocytochemistry staining SR-BI in PC-12 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Immunocytochemistry-Immunofluorescence-NBP3-11865-img0006.jpg)
![Immunohistochemistry-Paraffin: SR-BI Antibody (SR37-06) [NBP3-11865] - Immunohistochemical analysis of paraffin-embedded mouse liver tissue using NBP3-11865. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Immunohistochemistry-Paraffin-NBP3-11865-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: SR-BI Antibody (SR37-06) [NBP3-11865] - Immunocytochemistry staining SR-BI in CRC cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Immunocytochemistry-Immunofluorescence-NBP3-11865-img0005.jpg)
![Immunohistochemistry-Paraffin: SR-BI Antibody (SR37-06) [NBP3-11865] - Immunohistochemical analysis of paraffin-embedded human liver tissue using NBP3-11865. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Immunohistochemistry-Paraffin-NBP3-11865-img0002.jpg)
![Immunohistochemistry-Paraffin: SR-BI Antibody (SR37-06) [NBP3-11865] - Immunohistochemical analysis of paraffin-embedded human spleen tissue using NBP3-11865. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/SR-BI-Antibody-SR37-06-Immunohistochemistry-Paraffin-NBP3-11865-img0003.jpg)
![Western Blot: BRAF35 Antibody (1F6) [H00010362-M01] - HMG20B monoclonal antibody (M01), clone IF6 Analysis of HMG20B expression in HeLa.](http://images.novusbio.com/fullsize/BRAF35-Antibody-1F6-Western-Blot-H00010362-M01-img0010.jpg "Western Blot: BRAF35 Antibody (1F6) [H00010362-M01] - HMG20B monoclonal antibody (M01), clone IF6 Analysis of HMG20B expression in HeLa.")
![Immunocytochemistry/Immunofluorescence: BRAF35 Antibody (1F6) [H00010362-M01] - Analysis of monoclonal antibody to HMG20B on HeLa cell. Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/BRAF35-Antibody-1F6-Immunocytochemistry-Immunofluorescence-H00010362-M01-img0007.jpg)
![Immunohistochemistry-Paraffin: BRAF35 Antibody (1F6) [H00010362-M01] - Analysis of monoclonal antibody to HMG20B on formalin-fixed paraffin-embedded human lung cancer. Antibody concentration 1.8 ug/ml.](http://images.novusbio.com/fullsize/BRAF35-Antibody-1F6-Immunohistochemistry-Paraffin-H00010362-M01-img0009.jpg)
![Western Blot: BRAF35 Antibody (1F6) [H00010362-M01] - Western blot analysis of HMG20B in extracts from 293T, HeLa and A549 cell using anti-HMG20B monoclonal antibody ( Cat # L013V1 ).](http://images.novusbio.com/fullsize/BRAF35-Antibody-1F6-Western-Blot-H00010362-M01-img0001.jpg)
![Western Blot: BRAF35 Antibody (1F6) [H00010362-M01] - Analysis of HMG20B in extracts from 293T, HeLa and A549 cell using anti-HMG20B monoclonal antibody.](http://images.novusbio.com/fullsize/BRAF35-Antibody-1F6-Western-Blot-H00010362-M01-img0011.jpg)
![Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Membrane attack complex-induced and endosome-dependent stabilization of ZFYVE21. Human umbilical vein endothelial cells (HUVECs) were treated with panel reactive antibody (PRA) sera (25% v/v in gelatin veronal buffer) (a). HUVECs were treated with MG132 (25uM). Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-10041-2), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZFYVE21-Antibody-Western-Blot-H00079038-B01P-img0005.jpg "Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Membrane attack complex-induced and endosome-dependent stabilization of ZFYVE21. Human umbilical vein endothelial cells (HUVECs) were treated with panel reactive antibody (PRA) sera (25% v/v in gelatin veronal buffer) (a). HUVECs were treated with MG132 (25uM). Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-10041-2), licensed under a CC-BY license.")
![Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Analysis of ZFYVE21 expression in transfected 293T cell line by ZFYVE21 polyclonal antibody. Lane 1: ZFYVE21 transfected lysate(25.74 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/ZFYVE21-Antibody-Western-Blot-H00079038-B01P-img0002.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Correlations of ZFYVE21 and complement in patient tissues. Western blots of human umbilical vein endothelial cells treated with either panel reactive antibody (30min, 25% v/v in gelatin veronal buffer) or LIGHT (12h, 50ng/mL in EGM2 media, a). Kidney biopsies from renal transplant patients (n=12) were stained as indicated. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-10041-2), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZFYVE21-Antibody-Western-Blot-H00079038-B01P-img0003.jpg)
![Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Recombinant FLAG-tagged ZFYVE21 (1ug) and/or recombinant SMURF2 (1ug) protein was incubated for 30min at room temperature and analyzed by western blot. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-019-10041-2), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZFYVE21-Antibody-Western-Blot-H00079038-B01P-img0004.jpg)
![Western Blot: ZFYVE21 Antibody [H00079038-B01P] - Correlations of ZFYVE21 & complement in patient tissues. Western blots of human umbilical vein endothelial cells treated with either panel reactive antibody (30 min, 25% v/v in gelatin veronal buffer) or LIGHT (12 h, 50 ng/mL in EGM2 media, a). Kidney biopsies from renal transplant patients (n = 12) were stained as indicated (b). Synovial biopsies from osteoarthritis (n = 11), low-titer rheumatoid factor antibody rheumatoid arthritis (RF RA; n = 8), & high-titer RF RA (n = 8) were stained as indicated (c–e) & spatial correlations between ZFVYE21 or nuclear factor-inducing kinase (NIK) with endothelial cells (Ulex, f) & membrane attack complex (polyC9, g) were assessed using the computer software (scale bar: 200 μm). ****p < 1 × 10−5, Student’s t test. CD45 abundance was assessed (h) & correlated with NIK staining (i) via blinded scoring from three independent observers. *p < 0.05, **p < 0.001. Western blotting was repeated three times. Analysis of variance statistical analyses were performed. Representative data shown *p < 0.05, **p < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31113953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00079038-b01p_mouse-polyclonal-zfyve21-antibody-31020241548367.jpg)
![Western Blot: ZFYVE21 Antibody [H00079038-B01P] - SMURF2-dependent degradation of vesicular PTEN. PTEN co-immunoprecipitations (co-IPs) were performed on human umbilical vein endothelial cells (HUVECs) treated for 30 min with panel reactive antibody (PRA) sera & blotted as indicated (a). Rab5 co-IPs were performed on PRA-treated HUVECs transfected with control or SMURF2 siRNA (b). Western blot analysis of whole-cell lysates of HUVECs transiently transfected with SMURF2 WT, SMURF2 DN, control siRNA, & SMURF2 siRNA (c). HUVECs transfected with control, SMURF2, or ZFYVE21 siRNA were treated with PRA & Rab5 co-IPs were performed (d). Recombinant FLAG-tagged ZFYVE21 (1 μg) and/or recombinant SMURF2 (1 μg) protein was incubated for 30 min at room temperature & analyzed by western blot (e). In vitro kinase assays were performed using various E2 ubiquitin ligases with SMURF2 protein (1 μg) as the E3 ubiquitin ligase & PTEN (1 μg) as substrate (f). In vitro kinase assays were performed using isolated SMURF2 WT or SMURF2 DN as E3 ubiquitin ligases, UbcH5c as the E2 ubiquitin ligase, & PTEN as substrate as indicated (g). HUVECs were pretreated with MG132 for 4 h or chloroquine for 30 min prior to PRA treatment at the indicated times prior to Rab5 co-IP & western blot analysis (h). Western blot analyses were repeated two to four times. Confocal microscopic studies analyzed ≥4 cells per group & was repeated three times. In vitro kinase assays were repeated twice. Representative data shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31113953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00079038-b01p_mouse-polyclonal-zfyve21-antibody-310202415485117.jpg)
![Western Blot: Vasohibin Antibody (4A3) [H00022846-M05] - Analysis of VASH1 expression in HepG2 (Cat # L019V1).](http://images.novusbio.com/fullsize/Vasohibin-Antibody-4A3-Western-Blot-H00022846-M05-img0004.jpg "Western Blot: Vasohibin Antibody (4A3) [H00022846-M05] - Analysis of VASH1 expression in HepG2 (Cat # L019V1).")
![Immunohistochemistry-Paraffin: Vasohibin Antibody (4A3) [H00022846-M05] - Analysis of monoclonal antibody to VASH1 on formalin-fixed paraffin-embedded human salivary gland. Antibody concentration 3 ug/ml](http://images.novusbio.com/fullsize/Vasohibin-Antibody-4A3-Immunohistochemistry-Paraffin-H00022846-M05-img0002.jpg)
![Sandwich ELISA: Vasohibin Antibody (4A3) [H00022846-M05] - Detection limit for recombinant GST tagged VASH1 is 0.03 ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/Vasohibin-Antibody-4A3-Sandwich-ELISA-H00022846-M05-img0003.jpg)